Ling-Long Tang is a“Changjiang (Yangtze River) Scholar”Distinguished Professor, an honor awarded by the Ministry of Education of China. She holds several key committee positions that reflect her national influence in shaping clinical standards and research directions for nasopharyngeal carcinoma (NPC), including Member of the Youth Committee of the Chinese Society for Radiation Oncology (CSTRO), Committee Member of the Nasopharyngeal Carcinoma Committee of the Chinese Society of Clinical Oncology (CSCO), Committee Member of the Nasopharyngeal Carcinoma Committee of the Chinese Anti-Cancer Association (CACA), and Chairperson of the Youth Committee of the Nasopharyngeal Carcinoma Society of the Guangdong Provincial Medical Association.

She serves as a reviewer and editorial board member for numerous peer-reviewed journals. As first author and/or corresponding author, Professor Tang has published more than 50 papers in prestigious international peer-reviewed journals, including CA: A Cancer Journal for Clinicians, JAMA, Journal of Clinical Oncology, The Lancet Oncology, Radiology, International Journal of Radiation Oncology•Biology•Physics, and Radiotherapy and Oncology.

Professor Tang’s primary research focuses on prognosis prediction and comprehensive treatment strategies for nasopharyngeal carcinoma. She has made substantial contributions to developing individualized radiotherapy strategies, which have significantly reduced treatment-related toxicity and improved patients’quality of life. She has served as Principal Investigator or Co-Principal Investigator for several multicenter clinical trials and translational research projects, including a Joint Fund Program of the National Natural Science Foundation of China (2025~2028) and a National Major Project for the Prevention and Treatment of Cancers, Cardio-Cerebrovascular, Respiratory, and Metabolic Diseases (2024~2028).

Her research achievements have been recognized with numerous awards, including two State Scientific and Technological Progress Awards (2023, 2009), three Chinese Medical Science and Technology Awards (2022, 2014, 2007), and two University Scientific and Technological Progress Awards from the Ministry of Education (2020, 2014).

Professor Tang graduated from Sun Yat-sen University in Guangzhou, China, in 2002. She subsequently earned her Master’s and Doctoral degrees in Oncology from the Sun Yat-sen University Cancer Center. She also completed a one-year visiting scholar fellowship in Radiation Oncology at the University of Texas MD Anderson Cancer Center in the United States.

1. Tang LL*#, Chen L*, Xu GQ*, Zhang N*, Huang CL*, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Y, Li JB, Liu N, Xie FY#, Guo R#, Sun Y#, Ma J#. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: an open-label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025 May-Jun;75(3):203-215. doi: 10.3322/caac.21881. Epub 2025 Feb 19.

2. Tang LL*, Huang CL*, Lin SJ*, Le QT*, O'Sullivan B*, Yom SS*, Huang SH*, Chan AW*, Lee N*, Pan JJ*, Mejia MBA, Ahn YC, Wong KCW, McDowell L, Orlandi E, Friborg J, Chen YP, Yasuda K, Kodaira T, Whitley AC, King AD, Prajogi GB, Hahn E, Lin JC, Kiyota N, Lee V, Ji PJ, Hitchcock Y, Hoebers F, Blanchard P, Moon SH, Wan Ishak WZ, Harrington KJ, Yang KY, Colevas AD, Lee A, Hu CS, Rosenthal D, Siddiqui F, Langendijk JA, Lang JY, Yi JL, Shen LF, Li JB, Liu LZ, Lee AWM, Mai HQ, Yang MK, Sun Y#, Chua MLK#, Ma# J.Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.Lancet Oncol. 2025 Sep;26(9):e477-e487. doi: 10.1016/S1470-2045(25)00326-2.

3. Tang LL*, Huang CL*, Lin SJ*, Le QT*, O'Sullivan B*, Yom SS*, Huang SH*, Chan AW*, Lee N*, Pan JJ*, Mejia MBA, Ahn YC, Wong KCW, McDowell L, Orlandi E, Friborg J, Chen YP, Yasuda K, Kodaira T, Whitley AC, King AD, Prajogi GB, Hahn E, Lin JC, Kiyota N, Lee V, Ji PJ, Hitchcock Y, Hoebers F, Blanchard P, Moon SH, Wan Ishak WZ, Harrington KJ, Yang KY, Colevas AD, Lee A, Hu CS, Rosenthal D, Siddiqui F, Langendijk JA, Lang JY, Yi JL, Shen LF, Li JB, Liu LZ, Lee AWM, Mai HQ, Yang MK, Sun Y#, Chua MLK#, Ma# J.Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.Lancet Oncol. 2025 Sep;26(9):e488-e498. doi: 10.1016/S1470-2045(25)00327-4.

4. Tang LL*, Guo R*, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y#, Ma J#. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022;328(8):728-736.

5. Huang CL*, Zhang N*, Jiang W*, Xie FY*, Pei XQ*, Huang SH, Wang XY, Mao YP, Li KP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Zhou GQ, Ma J, Sun Y, Chen L, Tang LL#.Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.J Clin Oncol. 2024;42(17):2021-2025.

6. Zhang Y*, Chen L*, Hu GQ*, Zhang N*, Zhu XD*, Yang KY*, Jin F*, Shi M*, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Xie FY, Sun Y, Ma J,Tang LL#. Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2022;40(22):2420-2425.

7. Tang LL*#, Huang CL*, Zhang N*, Jiang W*, Wu YS*, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L#, Zhou GQ#, Ma J#. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022;23(4):479-490.

8. Liu X*, Zhang Y*, Yang KY*, Zhang N*, Jin F*, Zou GR*, Zhu XD*, Xie FY*, Liang XY*, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL#, Chen YP#, Sun Y#, Ma J#. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2024;403(10445):2720-2731.

9. Mao YP*#, Wang SX*, Gao TS*, Zhang N*, Liang XY*, Xie FY*, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL#, Chen L#, Sun Y#, Ma J#. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023;380:e072133.

10. Tang LL*, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, Du XJ, Fang WF, Feng M, Gao J, Han F, He X, Hu CS, Hu DS, Hu GY, Jiang H, Jiang W, Jin F, Lang JY, Li JG, Lin SJ, Liu X, Liu QF, Ma L, Mai HQ, Qin JY, Shen LF, Sun Y, Wang PG, Wang RS, Wang RZ, Wang XS, Wang Y, Wu H, Xia YF, Xiao SW, Yang KY, Yi JL, Zhu XD, Ma J#. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (Lond). 2021;41(11):1195-1227.